Literature DB >> 34229295

Bi-directional relationships between co-morbid insomnia and sleep apnea (COMISA).

Alexander Sweetman1, Leon Lack2, R Doug McEvoy3, Simon Smith4, Danny J Eckert5, Amal Osman6, Jayne C Carberry7, Douglas Wallace8, Phuc D Nguyen9, Peter Catcheside10.   

Abstract

Insomnia and obstructive sleep apnea (OSA) commonly co-occur. Approximately 30-50% of patients with OSA report clinically significant insomnia symptoms, and 30-40% of patients with chronic insomnia fulfil diagnostic criteria for OSA. Compared to either insomnia or OSA alone, co-morbid insomnia and sleep apnea (COMISA) is associated with greater morbidity for patients, complex diagnostic decisions for clinicians, and reduced response to otherwise effective treatment approaches. Potential bi-directional causal relationships between the mechanisms and manifestations of insomnia and OSA could play an integral role in the development and management of COMISA. A greater understanding of these relationships is required to guide personalized diagnostic and treatment approaches for COMISA. This review summarizes the available evidence of bi-directional relationships between COMISA, including epidemiological research, case studies, single-arm treatment studies, randomized controlled treatment trials, and objective sleep study data. This evidence is integrated into a conceptual model of COMISA to help refine the understanding of potential bi-directional causal relationships between the two disorders. This theoretical framework is essential to help guide future research, improve diagnostic tools, determine novel therapeutic targets, and guide tailored sequenced and multi-faceted treatment approaches for this common, complex, and debilitating condition.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cognitive behavioral therapy for insomnia (CBTi); Continuous positive airway pressure (CPAP); Mechanisms; Precision medicine; Sleep disordered breathing; Upper airway

Mesh:

Year:  2021        PMID: 34229295     DOI: 10.1016/j.smrv.2021.101519

Source DB:  PubMed          Journal:  Sleep Med Rev        ISSN: 1087-0792            Impact factor:   11.609


  5 in total

Review 1.  More than sleepiness: prevalence and relevance of nonclassical symptoms of obstructive sleep apnea.

Authors:  Johan Verbraecken
Journal:  Curr Opin Pulm Med       Date:  2022-09-14       Impact factor: 2.868

2.  All-Cause Mortality in People with Co-Occurring Insomnia Symptoms and Sleep Apnea: Analysis of the Wisconsin Sleep Cohort.

Authors:  Bastien Lechat; Kelly A Loffler; Douglas M Wallace; Amy Reynolds; Sarah L Appleton; Hannah Scott; Andrew Vakulin; Nicole Lovato; Robert Adams; Danny J Eckert; Peter G Catcheside; Alexander Sweetman
Journal:  Nat Sci Sleep       Date:  2022-10-13

3.  Differences between subjective and objective sleep duration according to actual sleep duration and sleep-disordered breathing: the Nagahama Study.

Authors:  Naomi Takahashi; Takeshi Matsumoto; Yoshinari Nakatsuka; Kimihiko Murase; Yasuharu Tabara; Hirofumi Takeyama; Takuma Minami; Satoshi Hamada; Osamu Kanai; Kiminobu Tanizawa; Isuzu Nakamoto; Takahisa Kawaguchi; Kazuya Setoh; Takanobu Tsutsumi; Yoshimitsu Takahashi; Tomohiro Handa; Tomoko Wakamura; Naoko Komenami; Satoshi Morita; Toyohiro Hirai; Fumihiko Matsuda; Takeo Nakayama; Kazuo Chin
Journal:  J Clin Sleep Med       Date:  2022-03-01       Impact factor: 4.062

4.  Multinight Prevalence, Variability, and Diagnostic Misclassification of Obstructive Sleep Apnea.

Authors:  Bastien Lechat; Ganesh Naik; Amy Reynolds; Atqiya Aishah; Hannah Scott; Kelly A Loffler; Andrew Vakulin; Pierre Escourrou; R Doug McEvoy; Robert J Adams; Peter G Catcheside; Danny J Eckert
Journal:  Am J Respir Crit Care Med       Date:  2022-03-01       Impact factor: 30.528

5.  Aquaporin-4, Connexin-30, and Connexin-43 as Biomarkers for Decreased Objective Sleep Quality and/or Cognition Dysfunction in Patients With Chronic Insomnia Disorder.

Authors:  Shuai Yang; Xiao-Yi Kong; Ting Hu; Yi-Jun Ge; Xue-Yan Li; Jun-Tao Chen; Shuo He; Ping Zhang; Gui-Hai Chen
Journal:  Front Psychiatry       Date:  2022-03-25       Impact factor: 4.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.